Published in Med Sci Monit on April 22, 2016
The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther (2002) 4.73
BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am (2009) 1.74
GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget (2014) 1.56
The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. Science (2014) 1.37
Regulation of apoptosis and cell cycle progression by MCL1. Differential role of proliferating cell nuclear antigen. J Biol Chem (2000) 1.33
Retinoids: present role and future potential. Br J Cancer (1999) 1.28
Current treatment strategies for inhibiting mTOR in cancer. Trends Pharmacol Sci (2014) 1.26
Beyond BRAF: where next for melanoma therapy? Br J Cancer (2014) 1.26
RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy. Dermatol Res Pract (2011) 1.15
NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene (2012) 1.15
Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor. Oncologist (2015) 1.13
mTOR signaling in tumorigenesis. Biochim Biophys Acta (2014) 1.06
AKT kinase pathway: a leading target in cancer research. ScientificWorldJournal (2013) 1.01
Targeting NRAS in melanoma. Cancer J (2012) 1.00
Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition. Proc Natl Acad Sci U S A (2013) 0.98
A case of intracranial hemorrhage caused by combined dabrafenib and trametinib therapy for metastatic melanoma. Am J Case Rep (2014) 0.96
Retinoic acid receptors: from molecular mechanisms to cancer therapy. Mol Aspects Med (2014) 0.95
α-Mangostin suppresses the viability and epithelial-mesenchymal transition of pancreatic cancer cells by downregulating the PI3K/Akt pathway. Biomed Res Int (2014) 0.93
Increased diagnosis of thin superficial spreading melanomas: A 20-year study. J Am Acad Dermatol (2011) 0.93
Unlocking the potential of retinoic acid in anticancer therapy. Br J Cancer (2014) 0.90
Torin1-mediated TOR kinase inhibition reduces Wee1 levels and advances mitotic commitment in fission yeast and HeLa cells. J Cell Sci (2014) 0.89
Dual inhibition of (V600E)BRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism. Cancer Lett (2011) 0.88
Targeting truncated retinoid X receptor-α by CF31 induces TNF-α-dependent apoptosis. Cancer Res (2012) 0.88
Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma. Mol Cancer (2015) 0.87
Treatment of NRAS-mutant melanoma. Curr Treat Options Oncol (2015) 0.86
Comparison of the in vitro and in vivo effects of retinoids either alone or in combination with cisplatin and 5-fluorouracil on tumor development and metastasis of melanoma. Cancer Chemother Pharmacol (2008) 0.85
Variable effects of retinoids on two pigmenting human melanoma cell lines. Cancer Res (1982) 0.85
Vitamin A, cancer treatment and prevention: the new role of cellular retinol binding proteins. Biomed Res Int (2015) 0.85
Inhibitory effects of α-mangostin on mammalian DNA polymerase, topoisomerase, and human cancer cell proliferation. Food Chem Toxicol (2013) 0.84
Redox control of retinoic acid receptor activity: a novel mechanism for retinoic acid resistance in melanoma cells. Endocrinology (2001) 0.84
Xanthones from mangosteen (Garcinia mangostana): multi-targeting pharmacological properties. J Med Assoc Thai (2014) 0.84
Retinal toxicities of cancer therapy drugs: biologics, small molecule inhibitors, and chemotherapies. Retina (2014) 0.82
Retinoid resistance and multifaceted impairment of retinoic acid synthesis in glioblastoma. Glia (2015) 0.82
Longikaurin E induces apoptosis of pancreatic cancer cells via modulation of the p38 and PI3K/AKT pathways by ROS. Naunyn Schmiedebergs Arch Pharmacol (2015) 0.81
Down-regulation of deacetylase HDAC6 inhibits the melanoma cell line A375.S2 growth through ROS-dependent mitochondrial pathway. PLoS One (2015) 0.81
High-throughput, high-content screening for novel pigmentation regulators using a keratinocyte/melanocyte co-culture system. Exp Dermatol (2014) 0.81
Inhibition of cell proliferation, migration and invasion of B16-F10 melanoma cells by α-mangostin. Biochem Biophys Res Commun (2014) 0.80
α-Mangostin suppresses human gastric adenocarcinoma cells in vitro via blockade of Stat3 signaling pathway. Acta Pharmacol Sin (2014) 0.80
Vitamin A (retinoids) regulation of mouse melanoma growth and differentiation. J Nutr (2003) 0.80
Melanoma mutagenesis and aberrant cell signaling. Cancer Control (2013) 0.79
The combination of the antiestrogen endoxifen with all-trans-retinoic acid has anti-proliferative and anti-migration effects on melanoma cells without inducing significant toxicity in non-neoplasic cells. Eur J Pharmacol (2013) 0.79
Phase 2 trial of paclitaxel, 13-cis retinoic acid, and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancer. Int J Gynecol Cancer (2014) 0.78
Drug combo shows promise in NRAS-mutant melanoma. Cancer Discov (2014) 0.77
NRAS-mutant melanoma: response to chemotherapy. Arch Dermatol (2011) 0.77
NF-κB down-regulation and PARP cleavage by novel 3-α-butyryloxy-β-boswellic acid results in cancer cell specific apoptosis and in vivo tumor regression. Anticancer Agents Med Chem (2013) 0.76
Managing malignant melanoma. Plast Reconstr Surg (2014) 0.76
Inhibitory effects of p-alkylaminophenol on melanogenesis. Bioorg Med Chem (2014) 0.76